Final Overall Survival of the Phase III Randomised Trial of Chemotherapy with and without Bevacizumab for Advanced Cervical Cancer: An NRG Oncology/Gynecologic Oncology Group Study

BACKGROUND: On August 14, 2014, the United States Food and Drug Administration approved the anti-angiogenesis drug, bevacizumab, for women with advanced cervical cancer based on a 2012 interim analysis of 271 deaths on GOG protocol 240. We now report the planned protocol-specified final analysis of...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Lancet
Auteurs principaux: Tewari, Krishnansu S., Sill, Michael W., Penson, Richard T., Huang, Helen, Ramondetta, Lois M., Landrum, Lisa M., Oaknin, Ana, Reid, Thomas J., Leitao, Mario M., Michael, Helen E., DiSaia, Philip J., Copeland, Larry J., Creasman, William T., Stehman, Frederick B., Brady, Mark F., Burger, Robert A., Thigpen, J. Tate, Birrer, Michael J., Waggoner, Steven E., Moore, David H., Look, Katherine Y., Koh, Wui-Jin, Monk, Bradley J.
Format: Artigo
Langue:Inglês
Publié: 2017
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5714293/
https://ncbi.nlm.nih.gov/pubmed/28756902
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(17)31607-0
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires